Coverart for item
The Resource Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines

Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines

Label
Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Title
Clinical Trials
Title remainder
Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Creator
Subject
Genre
Language
eng
Summary
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understandi
Member of
Cataloging source
EBLCP
http://library.link/vocab/creatorName
Brody, Tom
Dewey number
  • 615.19
  • 615/.19
Index
no index present
LC call number
  • QV771
  • RS189
Literary form
non fiction
Nature of contents
dictionaries
http://library.link/vocab/subjectName
  • Clinical trials
  • Drug Approval
  • Research
  • Clinical Trials as Topic
  • Clinical Trials Data Monitoring Committees
  • Research Design
  • Delivery of Health Care
  • Quality of Health Care
  • Health Care Quality, Access, and Evaluation
  • Quality Assurance, Health Care
  • Health Care Evaluation Mechanisms
  • Drug and Narcotic Control
  • Evaluation Studies as Topic
  • Professional Staff Committees
  • Epidemiologic Study Characteristics as Topic
  • Methods
  • Epidemiologic Methods
  • Investigative Techniques
  • Legislation, Drug
  • Science
  • Public Health
  • Analytical, Diagnostic and Therapeutic Techniques and Equipment
  • Social Control, Formal
  • Natural Science Disciplines
  • Sociology
  • Disciplines and Occupations
  • Environment and Public Health
  • Social Sciences
  • Anthropology, Education, Sociology and Social Phenomena
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • Clinical trials
  • Medicine
  • Health & Biological Sciences
  • Medical Research
Label
Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Instantiates
Publication
Note
G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin
  • D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema
  • C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"?
  • M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control
  • C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug
Control code
763157847
Dimensions
unknown
Extent
1 online resource (673 pages)
Form of item
online
Isbn
9780123919137
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
http://library.link/vocab/ext/overdrive/overdriveId
f40b9928-6490-4416-923b-94b4b8d4fc08
Specific material designation
remote
System control number
(OCoLC)763157847
Label
Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Publication
Note
G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin
  • D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema
  • C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"?
  • M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control
  • C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug
Control code
763157847
Dimensions
unknown
Extent
1 online resource (673 pages)
Form of item
online
Isbn
9780123919137
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
http://library.link/vocab/ext/overdrive/overdriveId
f40b9928-6490-4416-923b-94b4b8d4fc08
Specific material designation
remote
System control number
(OCoLC)763157847

Library Locations

    • UMKCBorrow it
      800 E 51st St, Kansas City, MO, 64110, US
      39.035061 -94.576518
    • Health Sciences LibraryBorrow it
      2411 Holmes St, Kansas City, Kansas City, MO, 64108, US
      39.083418 -94.575323
    • Leon E. Bloch Law LibraryBorrow it
      500 E. 52nd Street, Kansas City, MO, 64110, US
      39.032488 -94.581967
Processing Feedback ...